← ANALYSTS · TIPRANKS
Gregory Renza · Truist Financial
Hits
55%
260 of 477 ratings made money (TipRanks, all the analyst’s ratings)
Average return of a rating
+18.8%
Over a year after the rating, TipRanks’ measure
Our companies rated now
22
Buy / hold / sell: 19 / 3 / 0
Upside of the analyst’s targets
+61.1%
Average over 16 current targets, to the last price
The market’s answer to the ratings
+3.1%
Day-0 move against SPY in the rating’s direction, average over 15 upgrades, downgrades and target changes
| Date · added, NY | Stock | Action | Rating | Price target | Upside | Move vs SPY | |
|---|---|---|---|---|---|---|---|
| Oct 13on TipRanks 07:50 | CATXIWMPerspective Therapeutics · $267M | Reiterated | Buy | $11.00 | +406.9% | −9.9%next day −0.2% | ↗ |
| Oct 13on TipRanks 07:50 | NRIXIWMNurix Therapeutics · $2.7B | Reiterated | Buy | $34.00 → $33.00−2.9% | +35.1% | −0.1%next day +8.0% | ↗ |
| Oct 8on TipRanks 22:25 | MNKDIWMMannKind · $971M | Reiterated | Buy | $6.00 → $5.00−16.7% | +64.5% | −4.4%next day −4.8% · 5 days −5.6% | ↗ |
| Oct 8on TipRanks 22:25 | GMABGenmab · $22.3B | Reiterated | Buy | $40.00 → $45.00+12.5% | +21.6% | +2.2%next day +0.9% · 5 days +1.8% | ↗ |
| Oct 8on TipRanks 22:25 | ONCBeOne Medicines · $40.3B | Reiterated | Buy | $418 → $420+0.5% | +13.8% | +0.6%next day −1.1% · 5 days +6.1% | ↗ |
| Oct 7on TipRanks 09:10 | ZYMEIWMZymeworks · $1.8B | Reiterated | Buy | $32.00 → $34.00+6.2% | +35.8% | +3.7%next day −4.4% · 5 days −5.7% | ↗ |
| Oct 7on TipRanks 09:10 | EXELExelixis · $14.8B | Reiterated | Hold | $52.00 → $54.00+3.8% | −13.2% | +0.4%next day +1.4% · 5 days +5.3% | ↗ |
| Oct 7on TipRanks 09:10 | JAZZJazz Pharmaceuticals · $13.9B | Reiterated | Buy | $281 → $286+1.8% | +36.0% | +0.2%next day −3.4% · 5 days −8.3% | ↗ |
| Oct 7on TipRanks 09:10 | VKTXViking Therapeutics · $3.4B | Reiterated | Buy | $87.00 → $85.00−2.3% | +237.7% | +0.8%next day −2.4% · 5 days −9.8% | ↗ |
| Oct 7on TipRanks 09:10 | AGIOIWMAgios Pharma · $1.8B | Reiterated | Buy | $39.00 → $37.00−5.1% | +18.1% | +0.5%next day +0.8% · 5 days −1.6% | ↗ |
| Oct 7on TipRanks 09:05 | RVMDRevolution Medicines · $41.5B | Reiterated | Buy | $239 → $240+0.4% | +34.9% | +0.7%next day −5.9% · 5 days −2.7% | ↗ |
| Oct 7on TipRanks 09:05 | GILDQQQSPYGilead Sciences · $195B | Reiterated | Buy | $150 → $158+5.3% | +1.2% | +2.1%next day +0.6% · 5 days +5.5% | ↗ |
| Oct 7on TipRanks 09:05 | REGNQQQSPYRegeneron · $82.0B | Reiterated | Buy | $772 → $780+1.0% | −1.4% | +0.7%next day +0.1% · 5 days +5.9% | ↗ |
| Oct 7on TipRanks 09:05 | AMGNQQQSPYAmgen · $235B | Reiterated | Hold | $362 → $380+5.0% | −12.1% | +2.8%next day −0.9% · 5 days +4.1% | ↗ |
| Oct 5on TipRanks 08:45 | ONCBeOne Medicines · $40.3B | Reiterated | Buy | — | — | +0.3%next day −0.2% · 5 days −3.5% | ↗ |
| Oct 5on TipRanks 08:45 | GMABGenmab · $22.3B | Reiterated | Buy | — | — | +10.1%next day −2.3% · 5 days −3.3% | ↗ |
| Oct 2on TipRanks 07:35 | REGNQQQSPYRegeneron · $82.0B | Reiterated | Buy | $772 | −2.4% | −0.7%next day −1.9% · 5 days +0.4% | ↗ |
| Sep 30on TipRanks 13:15 | MNKDIWMMannKind · $971M | Reiterated | Buy | $6.00 | +97.4% | +17.0%next day +1.1% · 5 days −13.5% | ↗ |
| Sep 29on TipRanks 07:30 | ZYMEIWMZymeworks · $1.8B | Reiterated | Buy | $32.00 | +27.8% | +0.5%next day −2.4% · 5 days −7.6% | ↗ |
| Sep 28on TipRanks 07:30 | XNCRIWMXencor · $1.8B | Reiterated | Buy | $27.00 → $29.00+7.4% | +26.9% | +8.3%next day −2.2% · 5 days −1.1% | ↗ |
| Sep 23on TipRanks 07:55 | AMGNQQQSPYAmgen · $235B | Reiterated | Hold | — | — | −0.3%next day +0.1% · 5 days +4.5% | ↗ |
| Sep 23on TipRanks Sep 22 10:55 | VKTXViking Therapeutics · $3.4B | Reiterated | Buy | $83.00 → $87.00+4.8% | +245.6% | +35.7%next day +2.7% · 5 days −20.9% | ↗ |
| Sep 22on TipRanks 07:35 | ABVXAbivax SA Sponsored ADR · $8.6B | Reiterated | Buy | $155 → $151−2.6% | +71.3% | −5.0%next day −3.5% · 5 days +1.4% | ↗ |
| Sep 15on TipRanks 07:45 | NUVBIWMNuvation Bio · $1.7B | Reiterated | Buy | — | — | −1.9%next day +0.1% · 5 days +2.8% | ↗ |
| Sep 15on TipRanks 07:45 | CATXIWMPerspective Therapeutics · $267M | Reiterated | Buy | — | — | −6.0%next day −0.7% · 5 days +6.1% | ↗ |
| Sep 10on TipRanks 08:45 | CGONIWMCG Oncology, Inc. · $5.5B | Reiterated | Buy | — | — | +0.7%next day −0.4% · 5 days +4.4% | ↗ |
| Sep 3on TipRanks 08:15 | RVMDRevolution Medicines · $41.5B | Reiterated | Buy | — | — | −0.3%next day 0.0% · 5 days −2.2% | ↗ |
| Sep 1on TipRanks 08:05 | JAZZJazz Pharmaceuticals · $13.9B | Reiterated | Buy | — | — | −2.1%next day +0.3% · 5 days −1.1% | ↗ |
| Sep 1on TipRanks 08:05 | VRDNIWMViridian Therapeutics · $2.2B | Reiterated | Buy | — | — | +0.1%next day −1.5% · 5 days −1.4% | ↗ |
| Sep 1on TipRanks 08:05 | IDYAIWMIDEAYA Biosciences · $3.3B | Reiterated | Buy | — | — | +0.3%next day +0.1% · 5 days −4.1% | ↗ |
| Aug 28on TipRanks 08:55 | GILDQQQSPYGilead Sciences · $195B | Reiterated | Buy | — | — | −1.9%next day +0.8% · 5 days +3.5% | ↗ |
| Aug 21on TipRanks 07:55 | AAPGAscentage Pharma Group International Unsponsored ADR · $1.4B | Reiterated | Buy | — | — | −2.3%next day −1.4% · 5 days +7.0% | ↗ |
| Aug 18on TipRanks 08:25 | FULCIWMFulcrum Therapeutics · $280M | Reiterated | Hold | — | — | +1.5%next day +0.8% · 5 days −0.1% | ↗ |
| Aug 12on TipRanks 08:45 | GMABGenmab · $22.3B | Reiterated | Buy | — | — | +1.6%next day −1.0% · 5 days +9.0% | ↗ |
| Aug 11on TipRanks 08:45 | AGIOIWMAgios Pharma · $1.8B | Reiterated | Buy | — | — | +0.6%next day +4.4% · 5 days +5.6% | ↗ |
| Aug 6on TipRanks Aug 5 08:35 | ONCBeOne Medicines · $40.3B | Reiterated | Buy | $416 → $418+0.5% | +13.3% | +1.6%next day +0.9% · 5 days +9.3% | ↗ |
| Jul 31on TipRanks 07:36 | REGNQQQSPYRegeneron · $82.0B | Reiterated | Buy | $769 → $772+0.4% | −2.4% | +2.6%next day −1.9% · 5 days −0.7% | ↗ |
| Jul 10on TipRanks 07:27 | NRIXIWMNurix Therapeutics · $2.7B | Reiterated | Buy | $32.00 → $34.00+6.2% | +39.2% | −7.0%next day −0.8% · 5 days +1.8% | ↗ |
| No ratings for this filter. | |||||||
Ratings of the stocks the collector reads (the companies of QQQ, SPY, IWM, SMH, SOXL and SOXS and the other US stocks of TipRanks’ feed of new ratings) that it has kept: every new one since 30 September 2026, before that the analyst’s latest rating of each company. Upside is the target over the stock’s last price. The analyst at TipRanks ↗